Advancedadvanced biology

Complement: Three Pathways, One Cascade

Learning objectives

  • Distinguish the initiation mechanisms of the classical, lectin, and alternative pathways.
  • Explain C3 and C5 convertase assembly and the amplification loop.
  • Describe MAC formation and the effector functions of opsonization and anaphylatoxins.
  • Evaluate the regulatory proteins that protect host cells.
  • Relate complement dysregulation to disease and therapeutics.

Three on-ramps to C3

The complement system -- some 30 plasma and membrane proteins -- activates through three initiation pathways that converge at the cleavage of C3, the cascade's central hub. The classical pathway starts when C1q binds antibody-antigen complexes (IgM or clustered IgG), activating the C1r/C1s proteases, which cleave C4 and C2 to build the classical C3 convertase, C4b2a. The lectin pathway is the antibody-independent twin: mannose-binding lectin (MBL) or ficolins recognize microbial carbohydrate patterns and activate MASP proteases, which also cleave C4 and C2 -- same convertase, different sensor. The alternative pathway is the odd one: it needs no sensor at all. C3 undergoes slow spontaneous hydrolysis in plasma ('tickover'), and the resulting C3(H2O) binds factor B, which factor D cleaves to form a fluid-phase C3 convertase -- constantly probing. If this happens on a pathogen surface, properdin stabilizes the convertase; on host cells, regulators destroy it. The alternative pathway is thus both an initiator and, crucially, an amplifier of the other two.

Convertases and the amplification loop

C3 convertases cleave C3 into C3a (a small inflammatory mediator) and C3b (the business end), which covalently attaches to nearby surfaces through a reactive thioester -- painting the target for destruction. Here the alternative pathway's genius appears: surface-bound C3b binds factor B, factor D cleaves it, and a new alternative C3 convertase (C3bBb) is born -- which makes more C3b, which makes more convertase. This positive feedback loop means that even a trickle of initial C3b -- from tickover, or from classical/lectin activation -- explodes into dense C3b coating within minutes. The loop is why the alternative pathway, though 'spontaneous,' accounts for the majority of complement activation in most responses: it amplifies everyone. When C3b density rises high enough, convertases gain a new specificity: incorporating an extra C3b converts C3 convertases into C5 convertases (C4b2a3b or C3bBb3b), which cleave C5 into C5a (a potent chemoattractant and anaphylatoxin) and C5b -- the seed of the membrane attack complex. One protein's cleavage, two convertase specificities, three effector arms: the cascade's economy is remarkable.

The membrane attack complex and other effectors

C5b initiates MAC assembly: it recruits C6 and C7, and the C5b-7 complex inserts into the target membrane; C8 joins, and then 10-18 molecules of C9 polymerize into a ring, punching a ~10-nanometer pore through the membrane. Osmotic lysis follows -- the classic complement killing, devastating to Gram-negative bacteria (whose outer membrane is exposed) though less effective against Gram-positive bacteria shielded by thick peptidoglycan. But lysis is only one effector arm. Opsonization -- C3b (and its fragments iC3b, C3dg) coating the pathogen -- is arguably more important: phagocytes bearing complement receptors (CR1, CR3, CR4) engulf opsonized targets avidly, and this operates against virtually all pathogens. The anaphylatoxins C3a and C5a recruit and activate leukocytes, increase vascular permeability, and trigger mast-cell degranulation -- the inflammatory context that makes the whole response effective. Complement is thus simultaneously a killer, a tagger, and an alarm.

Regulators: aiming the weapon outward

An amplifying cascade that punches holes in membranes must be aimed -- host cells are bathed in the same plasma. Regulation is layered. In fluid phase, factor H recognizes host-specific surface chemistry (sialic acids, glycosaminoglycans) and, with factor I, inactivates C3b to iC3b -- which is why the tickover convertase survives only on unprotected surfaces. On membranes, DAF (CD55) accelerates convertase decay, MCP (CD46) serves as factor I cofactor, and CD59 (protectin) blocks C9 polymerization -- the last line, preventing MAC assembly on self. C1 inhibitor restrains the classical/lectin initiation proteases. The clinical proof of these regulators' necessity is in their failure: paroxysmal nocturnal hemoglobinuria (PNH) arises when hematopoietic stem cells lose the GPI anchor attaching CD55 and CD59 -- red cells without them are lysed by unrestrained complement, causing hemolytic anemia; atypical hemolytic uremic syndrome (aHUS) comes from factor H defects, with complement attacking the kidney endothelium. Regulation is not accessory -- it is what makes complement a weapon rather than a suicide system.

Complement in disease and therapy

Complement's therapeutic moment arrived with eculizumab, the anti-C5 antibody that transformed PNH from a frequently fatal disease into a manageable one -- and validated terminal-pathway blockade. The pipeline has since exploded: C3 inhibitors, factor B and factor D inhibitors for the alternative pathway, C1s inhibitors for classical-driven diseases, each matched to the pathway driving pathology. Age-related macular degeneration -- strongly associated with factor H polymorphisms -- is now treated with complement inhibitors delivered intraocularly. In infections, complement deficiencies reveal non-redundant roles: terminal-pathway (C5-C9) defects cause recurrent Neisserial infections, since MAC lysis is uniquely important against these bacteria. Excessive complement also drives pathology in reperfusion injury, transplant rejection, and severe infections where the anaphylatoxin storm outpaces its usefulness. The modern view treats complement as a tunable system -- three initiators, one amplifier, three effectors, layered brakes -- whose pharmacology is finally catching up to its biology.

Amplification is the real pathway

The alternative pathway's positive feedback loop amplifies initial C3b deposition from any source -- most complement activation in vivo runs through this loop regardless of which pathway started it.

Key points

  • Three initiators converge on C3: classical (C1q-antibody), lectin (MBL-microbial sugars), and alternative (spontaneous tickover) -- all building C3 convertases.
  • The alternative pathway's C3b-driven positive feedback loop amplifies all complement activation; dense C3b converts C3 convertases into C5 convertases.
  • Effectors: MAC (C5b-9) lyses targets, C3b opsonizes for phagocytosis, C3a/C5a drive inflammation and chemotaxis.
  • Regulators aim the cascade: factor H/I in fluid phase; CD55, CD46, CD59 on membranes; C1 inhibitor at initiation.
  • PNH (lost CD55/CD59) and aHUS (factor H defects) prove regulation is essential; eculizumab (anti-C5) and newer pathway-specific inhibitors are now therapeutic.

Common misconceptions

✗ Myth: The three complement pathways work independently.

✓ Truth: They converge at C3, and the alternative pathway's amplification loop magnifies activation from all three -- most in vivo activity flows through the shared amplifier.

✗ Myth: Complement's main job is punching holes in bacteria.

✓ Truth: Opsonization for phagocytosis and anaphylatoxin-driven inflammation are equally important effector arms -- and more broadly effective across pathogen types.

✗ Myth: Complement attacks anything it touches.

✓ Truth: Layered regulators (factor H/I, CD55, CD46, CD59) continuously disarm it on host surfaces; disease like PNH shows what happens when the brakes fail.

Frequently asked questions

How do the three pathways differ?

Classical starts with C1q binding antibody complexes; lectin with MBL/ficolins binding microbial sugars; alternative with spontaneous C3 tickover. Classical and lectin build C4b2a; alternative builds C3bBb -- all cleave C3.

What is the amplification loop?

Surface C3b binds factor B, which factor D cleaves, forming more C3 convertase -- a positive feedback loop that explosively coats targets with C3b regardless of which pathway initiated.

What does the membrane attack complex do?

C5b recruits C6, C7, C8, then polymeric C9 to punch a pore in the target membrane, causing osmotic lysis -- most effective against Gram-negative bacteria.

How are host cells protected?

Factor H/I inactivate C3b in fluid phase on host surfaces; membrane CD55 decays convertases, CD46 assists factor I, and CD59 blocks C9 polymerization -- layered brakes at every step.

What is PNH and how is it treated?

Paroxysmal nocturnal hemoglobinuria: loss of GPI-anchored CD55/CD59 leaves red cells defenseless against complement lysis. Anti-C5 eculizumab blocks terminal activation and transformed outcomes.